STAR Market tech board offers hope to Chinese venture capitalists

STAR Market tech board offers hope to Chinese venture capitalists
SHANGHAI/HONG KONG (Reuters) – When Chinese venture capital firm New Vision Capital invested in two startups focusing on cloud computing and micro-optics, the plan was to eventually take them public on the Nasdaq exchange. FILE PHOTO – A sign for STAR Market, China’s new Nasdaq-style tech board, is seen after the listing ceremony of the first batch of companies at... Read More

Bayer buys BlueRock in $600 million bet on stem cell therapies

Bayer buys BlueRock in $600 million bet on stem cell therapies
FRANKFURT (Reuters) – German drugmaker Bayer (BAYGn.DE) is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline. FILE PHOTO: The Bayer AG logo sits on display at the headquarters in La Garenne-Colombes, near Paris, France, May 13, 2019. REUTERS/Benoit Tessier/File... Read More

Coffee baron’s death fuels India Inc anger over govt crackdown on wrongdoing

Coffee baron’s death fuels India Inc anger over govt crackdown on wrongdoing
NEW DELHI (Reuters) – The apparent suicide of India’s coffee baron V.G. Siddhartha, under investigation by tax authorities, has inflamed anger toward the government among business leaders who feel it is going too far in its crackdown on fraud and tax evasion. The logo of Cafe Coffee Day is pictured at one of its outlets in Kolkata, India, July 31,... Read More

Coffee baron’s death fuels India Inc anger over government crackdown on wrongdoing

Coffee baron’s death fuels India Inc anger over government crackdown on wrongdoing
NEW DELHI (Reuters) – The apparent suicide of India’s coffee baron V.G. Siddhartha, under investigation by tax authorities, has inflamed anger toward the government among business leaders who feel it is going too far in its crackdown on fraud and tax evasion. The logo of Cafe Coffee Day is pictured at one of its outlets in Kolkata, India, July 31,... Read More

Amgen results beat estimates, lung cancer trial planned

Amgen results beat estimates, lung cancer trial planned
(Reuters) – Amgen Inc (AMGN.O) on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts. FILE PHOTO: An Amgen sign is seen at the company’s office in South San Francisco, California in this October 21, 2013 file photo. REUTERS/Robert Galbraith/Files... Read More

Amgen results beat estimates, cancer drug shows wider activity

Amgen results beat estimates, cancer drug shows wider activity
(Reuters) – Amgen Inc (AMGN.O) on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts. FILE PHOTO: An Amgen sign is seen at the company’s office in South San Francisco, California in this October 21, 2013 file photo. REUTERS/Robert Galbraith/Files... Read More

Amgen quarterly results beat estimates, but revenue dips 3%

Amgen quarterly results beat estimates, but revenue dips 3%
FILE PHOTO: An Amgen sign is seen at the company’s office in South San Francisco, California in this October 21, 2013 file photo. REUTERS/Robert Galbraith/Files (Reuters) – Amgen Inc (AMGN.O) on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts.... Read More

Biogen profit rises 72% on multiple sclerosis therapy sales

Biogen profit rises 72% on multiple sclerosis therapy sales
FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder (Reuters) – Biogen Inc (BIIB.O) posted a 72% rise in quarterly profit and lifted its 2019 earnings forecast on Tuesday, boosted by higher sales of its top-selling multiple sclerosis therapy Tecfidera. Shares of the company rose 5.4% to $244.99 before the bell, as... Read More

S&P ends near flat as Citigroup results sink banks; Nasdaq hits new high

S&P ends near flat as Citigroup results sink banks; Nasdaq hits new high
NEW YORK (Reuters) – The benchmark S&P 500 index ended little changed on Monday after oscillating between positive and negative territory throughout the session after Citigroup Inc (C.N) kicked off the earnings season with a mixed quarterly report. Traders work on the floor at the New York Stock Exchange (NYSE) in New York, U.S., July 1, 2019. REUTERS/Brendan McDermid The... Read More

S&P trades near flat as Citigroup results weigh on bank stocks

S&P trades near flat as Citigroup results weigh on bank stocks
NEW YORK (Reuters) – The benchmark S&P 500 index struggled for direction in choppy trade on Monday as earnings season began in earnest with a mixed quarterly report from Citigroup Inc (C.N). Traders work on the floor at the New York Stock Exchange (NYSE) in New York, U.S., July 1, 2019. REUTERS/Brendan McDermid The bank reported a better-than-expected profit but... Read More